The R&D Engine Behind the Platform.

This is not speculation. This is a preview of the foundational, peer-reviewed science that makes Ankylotron possible. This page is for the engineers, the scientists, and the investors who want to see the work.

From Monolithic Arrays to a Distributed 'Internet of Things' for the Brain.

The Problem

Traditional neural interfaces are monolithic, centralized, and lack spatial flexibility.

The Ankylotron Solution

The platform leverages a distributed network of autonomous, sub-millimeter, wireless micro-implants—"neurograins"—that act as a wireless sensor network for the nervous system.

Key Innovation: Dual-Protocol Comms

Our sophisticated, dual-protocol communication architecture demonstrates an application-aware engineering philosophy, recognizing that the requirements for "writing" signals (stimulation) and "reading" signals (recording) are fundamentally different.

Time-Division Multiple Access (TDMA)

For "writing." A synchronous, top-down protocol, ideal for precise, patterned stimulation and command-and-control.

Asynchronous Sparse Binary Identification Transmission (ASBIT)

For "reading." An event-driven, asynchronous protocol based on Code-Division Multiple Access (CDMA), elegantly optimized for large-scale recording of sparse neural spikes with high temporal fidelity and low power cost.

Key Innovation: Decoding

This deluge of data is useless without a decoder. Our data science pipeline validates the use of Long Short-Term Memory (LSTM) Recurrent Neural Networks (RNNs). These deep learning models can decode complex neural population activity in real-time, achieving a mean validation correlation of 0.72—significantly outperforming traditional linear filters.

Beyond Inert: Engineering a True Bio-Integrative Platform.

The Foreign Body Response (FBR)

Any long-term implant faces one great challenge: the Foreign Body Response (FBR). The body's immune system is evolved to attack any foreign object, forming a thick, dense, scar-like fibrous capsule that isolates the implant. This encapsulation leads to chronic inflammation, blocks sensor signals, and causes device failure. Traditional 'bio-inert' materials merely delay this; they don't solve it.

The Ankylotron FBR-Mitigation Strategy

Our solution is a comprehensive, multi-faceted strategy. We do not just block the FBR; we actively manage the host-material interface.

  1. Advanced Materials: Using Graphene-CNT composites and advanced polymers like PEEK that are inherently biocompatible.
  2. Mechanical Compliance: Engineering our flexible neural interfaces with a stiffness (Young's modulus) that closely matches that of nerve tissue, minimizing the chronic mechanical irritation that triggers FBR.
  3. Active Immunosuppression: Our R&D includes localized, slow-release anti-inflammatory drug coatings (e.g., dexamethasone) to actively modulate and suppress the initial aggressive phase of the immune response at the implant site.
  4. Surface Engineering: Coating our components with low-fouling biomaterials, such as zwitterionic hydrogels, to make them "stealthy" to the immune system by preventing the initial protein adsorption that triggers the FBR cascade.